Skip to main content

Table 2 Use of PIs among 679 subjects initiating PI-based HAART for HIV/AIDS at St Paul's Hospital, Vancouver, BC, August 1996 – January 2002

From: Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS

Characteristic*

 

Number of months between initiation of PI and end of observation, median (IQR)**

47 (29–62)

% of follow-up time with dispensed therapy mean (SD), median for PI

73 (30) 84

Mean (SD) number prescriptions for***

 

PI

31 (19)

% adherence in first year

 

mean (SD)

89 (21)

median (IQR)

100 (92 – 100)

  1. Abbreviations: SD = Standard deviation; IQR = Interquartile range; NRTI = nucleoside reverse transcriptase inhibitors; PI protease inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor
  2. * PIs available during follow-up included: indinavir, nelfinavir, saquinavir, and ritonavir. All data taken from time of first therapy initiation (treatment program enrollement).
  3. ** Time between first dispensation of HAART (enrollment) and last date of follow-up.
  4. *** All prescriptions are of 30 day duration
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X